Related to Geron’s hESC Therapy for Spinal Cord Injury Has Been Placed on Hold

• FDA Requests More Risk-Benefit Data for Amgen’s Xgeva sBLA in Prostate Cancer
  
• Novartis’ Afinitor Gets FDA Okay for Treating Renal Angiomyolipoma Associated with TSC
  
• GSK’s Votrient Approved in U.S. for Treating Soft Tissue Sarcoma
  
• Senate Appropriations Approves FDA Budget for FY 2013
  
• Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso
  
• Genzyme Gets FDA, EMA Approvals for Production Plant in Waterford, Ireland
  
• University of Miami’s Interdisciplinary Stem Cell Institute Awarded $10M
  
• CHI, BCG Issue Report on FDA's Drug Review Performance
  
• Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic Cancer Cell Therapy
  
• Osiris Wins Race to Market a Stem Cell Product with Canadian Go-Ahead
  
• MSC-Secreted Factor Key to Impact of Multiple Sclerosis Cell Therapy
  
• FDA Clears Novo Nordisk’s Levemir for Diabetic Children Aged Two Years and Over
  
• FDA Approves XenoPort, GSK’s Horizant for Managing Postherpetic Neuralgia
  
• FDA Clears Roche’s Perjeta as Combination Therapy for Metastatic Breast Cancer
  
• FDA Clears Immunetics' Rapid Test for Bacterial Contamination of Platelet Units
  
• FDA Approves GSK’s MenHibrix Meningitis Vaccine
  
• Cytori Adopts Sistemic's Platform for Stem Cells Trial
  
• FDA Fails to Back Janssen, Bayer’s Xarelto for Acute Coronary Syndrome
  
• NeoStem Wins $600K for Stem Cell Therapy Against Radiation Poisoning
  
• BMS, Pfizer Fail to Win FDA Sanction for Stroke Prevention Drug